Skip to main content
Home

Epocrates Online Contact us

  • Explore features
  • Reach clinicians
  • Buy now

Elicit hx of environmental food or contact allergies pursue testing only w concerning hx 1 5 in kids

Submitted by vgreene on Thu, 06/16/2022 - 11:36
  • Read more about Elicit hx of environmental food or contact allergies pursue testing only w concerning hx 1 5 in kids

Structured pt education recommended as adjunct to tx 1 nurse 5 or pharmacist led3 programs video interventions can be considered5

Submitted by vgreene on Thu, 06/16/2022 - 11:35
  • Read more about Structured pt education recommended as adjunct to tx 1 nurse 5 or pharmacist led3 programs video interventions can be considered5

Wet wrap tx w or w o TCS can be used to darr severity2

Submitted by vgreene on Thu, 06/16/2022 - 11:35
  • Read more about Wet wrap tx w or w o TCS can be used to darr severity2

Anti staph tx not routine Consider dilute bleach baths intranasal mupirocin in moderate dz w signs of secondary infxn per AAD 2 can consider more broadly per AAAAI although esp in pts w recurrent infxn 1 PO abx also appropriate w evidence of bacterial inf

Submitted by vgreene on Thu, 06/16/2022 - 11:34
  • Read more about Anti staph tx not routine Consider dilute bleach baths intranasal mupirocin in moderate dz w signs of secondary infxn per AAD 2 can consider more broadly per AAAAI although esp in pts w recurrent infxn 1 PO abx also appropriate w evidence of bacterial inf

If eczema herpeticum Use systemic antivirals3 4

Submitted by vgreene on Thu, 06/16/2022 - 11:33
  • Read more about If eczema herpeticum Use systemic antivirals3 4

Consider sedating PO antihistamines for pruritis esp if sleep interrupted1 3 4

Submitted by vgreene on Thu, 06/16/2022 - 11:32
  • Read more about Consider sedating PO antihistamines for pruritis esp if sleep interrupted1 3 4

Systemic agents indicated when optimized topical tx and or phototx don t adequately control dz or when severity of dz substantially impacts QoL1 4 Effective options incl cyclosporine modified MTX mycophenolate mofetil variably effective and azathioprine4

Submitted by vgreene on Thu, 06/16/2022 - 11:31
  • Read more about Systemic agents indicated when optimized topical tx and or phototx don t adequately control dz or when severity of dz substantially impacts QoL1 4 Effective options incl cyclosporine modified MTX mycophenolate mofetil variably effective and azathioprine4

Phototx 2nd line after failure of basic skin care TCS TCI 1 3 4 can be used as maintenance tx in chronic dz4

Submitted by vgreene on Thu, 06/16/2022 - 11:30
  • Read more about Phototx 2nd line after failure of basic skin care TCS TCI 1 3 4 can be used as maintenance tx in chronic dz4

TCIs a steroid sparing alternative 1 3 consider using to avoid skin atrophy on face eyelids skin folds when low potency TCS not effective 1 consider w periocular AD where TCS may also uarr risk of cataracts glaucoma 3 however TCIs may initially burn itch1

Submitted by vgreene on Thu, 06/16/2022 - 11:29
  • Read more about TCIs a steroid sparing alternative 1 3 consider using to avoid skin atrophy on face eyelids skin folds when low potency TCS not effective 1 consider w periocular AD where TCS may also uarr risk of cataracts glaucoma 3 however TCIs may initially burn itch1

Optimize TCS 1 2 consider pt age body area degree of xerosis pt preference cost when selecting TCS 2 3 typically lower potency in areas of thin skin face neck genitals skin folds 1 3 qd application may be as effective as bid 2 3 monitor PE for cutaneous A

Submitted by vgreene on Thu, 06/16/2022 - 11:28
  • Read more about Optimize TCS 1 2 consider pt age body area degree of xerosis pt preference cost when selecting TCS 2 3 typically lower potency in areas of thin skin face neck genitals skin folds 1 3 qd application may be as effective as bid 2 3 monitor PE for cutaneous A

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Current page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

About Us

  • Company Overview
  • Media Relations
  • Contact
  • Editorial Policy
  • Editorial Process
  • Third-Party Sponsorship Policy
  • athenahealth

Products

  • Core Products
  • Mobile CME
  • Product Licenses

Business Solutions

  • Pharma
  • Market Research
  • Institutions

Support

  • Support Center
  • Install
  • My Account

Stay Connected

Facebook Twitter YouTube

Patient Resource Footer Bottom

Show — Patient Resource Footer Bottom Hide — Patient Resource Footer Bottom
  • Privacy Policy
  • Terms of Use
  • Site Map